Order results by:
| Issue | Title | |
| Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
| I. A. Latfullin, A. A. Podolskaya | ||
| "... for glycoproteins GPIIb/IIIa. Possibility of clinical use of additional antiplatelet features of statines ..." | ||
| Vol 7, No 4 (2011) | ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID | Abstract similar documents |
| I. N. Bokarev, L. V. Popova | ||
| "... is highlighted. ASA modes of action and its position among the modern antiplatelet agents are considered ..." | ||
| Vol 7, No 1 (2011) | THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS | Abstract similar documents |
| O. V. Gaisenok | ||
| "... Current issues of atherothrombosis prevention and treatment optimization with antiplatelet therapy ..." | ||
| Vol 10, No 5 (2014) | DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| G. N. Guseva, T. V. Pavlova, I. L. Voronova, S. M. Chohlunov | ||
| "... Aim. To evaluate an adequacy of dual antiplatelet therapy (DAPT) in patients with acute coronary ..." | ||
| Vol 3, No 3 (2007) | RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov | ||
| "... to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have ..." | ||
| Vol 13, No 4 (2017) | PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW | Abstract similar documents |
| I. S. Yavelov | ||
| "... Prerequisites for the prolonged dual antiplatelet therapy after myocardial infarction are presented ..." | ||
| Vol 6, No 2 (2010) | THE MODERN ASPECTS OF CLOPIDOGREL USE | Abstract similar documents |
| E. N. Dankovtseva, D. A. Zateyshchikov | ||
| Vol 9, No 6 (2013) | ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS? | Abstract similar documents |
| Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein | ||
| "... heart disease after percutaneous coronary intervention and its contribution to antiplatelet therapy ..." | ||
| Vol 13, No 1 (2017) | MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya | ||
| "... to obtain the necessary information on the issue of control of antiplatelet therapy. The review brings ..." | ||
| Vol 10, No 6 (2014) | THE SIGNIFICANCE OF PLATELET FUNCTIONAL ACTIVITY TESTING IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS RECEIVING ANTIPLATELET THERAPY | Abstract similar documents |
| D. A. Andreev | ||
| "... complications in patients receiving antiplatelet therapy is presented. Indications for antiplatelet therapy ..." | ||
| Vol 16, No 6 (2020) | Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome | Abstract similar documents |
| R. M. Velieva, T. B. Pecherina, A. S. Vorobiev, V. V. Kashtalap, D. Yu. Sedykh | ||
| "... Today, optimal duration of double antiplatelet (DAPT) and triple antithrombotic therapy (TATT ..." | ||
| Vol 16, No 6 (2020) | Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? | Abstract similar documents |
| T. M. Uskach, A. S. Tereshchenko | ||
| "... Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment ..." | ||
| Vol 4, No 2 (2008) | ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION | Abstract similar documents |
| D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov | ||
| "... of antiplatelet therapy resistance is significantly higher in patients with diabetes mellitus and obesity (р<0 ..." | ||
| Vol 7, No 4 (2011) | VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY | Abstract similar documents |
| L. A. Haisheva, S. V. Shlyk | ||
| "... of revealed disorders with antiplatelet agent — clopidogrel 75 mg/day. Material and methods. 40 patients ..." | ||
| Vol 8, No 1 (2012) | RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION | Abstract similar documents |
| V. A. Sulimov, E. V. Moroz | ||
| "... of cardiovascular complications and activity of platelet aggregation, to assess safety of dual antiplatelet therapy ..." | ||
| Vol 15, No 5 (2019) | Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry | Abstract similar documents |
| Z. G. Tatarintseva, E. D. Kosmacheva, S. V. Kruchinova, V. A. Akinshina, A. A. Khalafyan | ||
| "... of Cardiology (ESC), patients with coexisting AF and ACS should receive dual antiplatelet therapy ..." | ||
| Vol 16, No 3 (2020) | A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study | Abstract similar documents |
| N. V. Lomakin, L. I. Buryachkovskaya, D. A. Zolin, V. I. Kazey | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , in rational pharmacotherapy in cardiology was shown on the example of its substrates – digoxin, antiplatelet ..." | ||
| Vol 14, No 2 (2018) | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. В. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, K. O. Tsukanova | ||
| "... in patients with stable angina significantly increased: antiplatelets – up to 82.7%, beta-blockers – up to 74 ..." | ||
| Vol 14, No 2 (2018) | New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion | Abstract similar documents |
| A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko | ||
| "... efficiency of present antiplatelet and anticoagulant drugs is shown in the key of preventing PAD thrombotic ..." | ||
| Vol 19, No 6 (2023) | Platelet phenotypes and practical aspects of platelet function testing in cardiology | Abstract similar documents |
| Zh. D. Kobalava, A. S. Pisaryuk, A. A. Filkova, E. S. Tukhsanboev, A. A. Boldyreva, D. P. Lazutova, I. A. Meray, M. A. Panteleev | ||
| "... the various consensus papers on assessing thrombotic and bleeding risk, monitoring antiplatelet therapy ..." | ||
| Vol 1, No 2 (2005) | STATINES IN PREVENTION AND TREATMENT OF ATHEROSCLEROSIS CONNECTED DISEASES: EFFICIENCY AND SAFETY | Abstract similar documents |
| Y. A. Karpov | ||
| "... of statines efficiency in prevention of ischemic heart disease (IHD), are analyzed. Decrease in risks ..." | ||
| Vol 20, No 6 (2024) | Platelet reactivity clinical and biochemical markers when taking acetylsalicylic acid as part of dual antiplatelet therapy in the myocardial infarction subacute period | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, A. V. Kapytski | ||
| "... antiplatelet therapy. Material and methods. 405 patients with MI (79.5% men and 20.5% women, average age 58 ..." | ||
| Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
| K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
| "... genes with the development of resistance to antiplatelet drugs in CHD patients. Material and Methods ..." | ||
| Vol 5, No 3 (2009) | ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 | Abstract similar documents |
| E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva | ||
| "... ,007 in G2). Conclusion. Resistance to antiplatelet drugs is observed more often in patients with DM2 ..." | ||
| Vol 11, No 4 (2015) | EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. V. Rudakova, N. V. Lomakin | ||
| "... Dual antiplatelet therapy, including clopidogrel and aspirin, in a significant share of patients ..." | ||
| Vol 11, No 1 (2015) | EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Andreev, D. A. Sychev | ||
| "... Evaluation of platelet function with subsequent modification of antiplatelet therapy regimen ..." | ||
| Vol 6, No 1 (2010) | ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... The problem of antiplatelet drug choice in patients with atrial fibrillation is discussed. Authors ..." | ||
| Vol 7, No 1 (2011) | NEW ANTIPLATELET DRUGS (PART 1) | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties ..." | ||
| Vol 7, No 5 (2011) | NEW ANTIPLATELET DRUGS. PART 2 | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern therapy of atherosclerosis ..." | ||
| Vol 11, No 2 (2015) | CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE | Abstract similar documents |
| K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva | ||
| "... antiplatelet drugs (acetylsalicylic acid and clopidogrel) and heparin. There were not any reasons ..." | ||
| Vol 8, No 2 (2012) | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev | ||
| "... Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel ..." | ||
| Vol 1, No 1 (2005) | NITRATES IN ISCHEMIC HEART DISEASE TREATMENT, YESTERDAY AND TODAY | Abstract similar documents |
| S. N. Tereschenko, N. A. Djaiani, E. V. Iljina | ||
| "... The problem of nitrate formulation choice in treatment of patients with ischemic heart disease ..." | ||
| Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
| E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
| "... as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often ..." | ||
| Vol 8, No 4 (2012) | ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE | Abstract similar documents |
| S. R. Gilyarevskiy, V. A. Orlov, I. M. Kuz'mina, A. G. Larin | ||
| "... Alternative approaches to the use of two component antiplatelet therapy in patients with acute ..." | ||
| Vol 6, No 4 (2010) | ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? | Abstract similar documents |
| S. J. Martsevich | ||
| Vol 15, No 2 (2019) | The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention | Abstract similar documents |
| A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov | ||
| "... . In addition to endovascular treatment, dual antiplatelet therapy plays a key role in the treatment ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... factors in plasma and vessel wall. Antiplatelet drugs do not always provide the necessary antithrombotic ..." | ||
| Vol 12, No 2 (2016) | ENDOTHELIAL DYSFUNCTION AND ROLE NITRATES AND BETA-BLOCKERS IN ITS CORRECTION IN ISCHEMIC HEART DISEASE | Abstract similar documents |
| A. N. Britov | ||
| "... . The treating effect of some medicinal products (nitrates, beta-blockers and others) is analyzed from the point ..." | ||
| Vol 12, No 4 (2016) | High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova | ||
| "... antiplatelet therapy (DAT) with acetylsalicylic acid (ASA) and clopidogrel by optical aggregometry in patients ..." | ||
| Vol 5, No 5 (2009) | EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi | ||
| "... and combined antiplatelet therapy (acetylsalicylic acid and clopidogrel). Material and methods. 98 patients ..." | ||
| Vol 13, No 2 (2017) | SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova | ||
| "... recommended for patients with a history of myocardial infarction (antiplatelets – 91.76%, beta-blockers – 83 ..." | ||
| Vol 7, No 6 (2011) | ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS | Abstract similar documents |
| L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..." | ||
| Vol 1, No 1 (2005) | ACE INHIBITORS IN PATIENTS WITH ISCHEMIC HEART DISEASE WITHOUT HEART FAILURE: CLASS EFFECTS AND EFFICACY OF ITS REPRESENTATIVES | Abstract similar documents |
| Y. A. Karpov | ||
| "... to antiplatelet, lipid reducing remedies and beta-blockers. ..." | ||
| Vol 12, No 5 (2016) | Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome | Abstract similar documents |
| I. Yu. Grinshtein, A. A. Savchenko, Yu. I. Grinshtein, M. M. Petrova | ||
| "... method in the first day of ACS before antiplatelet therapy and on day 10. Results. Increase ..." | ||
| Vol 9, No 6 (2013) | DYNAMICS IN MEDICAL TREATMENT OF ISCHEMIC HEART DISEASE IN CLINICAL PRACTICE | Abstract PDF (Eng) similar documents |
| S. A. Shalnova, A. D. Deev, S. A. Boytsov | ||
| "... .4% of the IHD patients received no medications. Statins intake increased from 5.3% to 85.7% in men and from 9 ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| Vol 13, No 6 (2017) | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE | Abstract similar documents |
| A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina | ||
| "... of antiplatelet therapy in patients with acute coronary syndrome (ACS) in routine practice. Material and methods ..." | ||
| Vol 9, No 1 (2013) | POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova | ||
| "... and induced flow cytofluorometry during antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA ..." | ||
| Vol 9, No 4 (2013) | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev | ||
| "... is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 testing, as well ..." | ||
| Vol 14, No 2 (2018) | DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT | Abstract similar documents |
| N. В. Perepech, A. V. Tregubov | ||
| "... Aim. To study the doctors' opinions on the main aspects of antiplatelet agents use, and to test ..." | ||
| Vol 4, No 1 (2008) | COMPARISON OF ANTIPLATELET EFFECT AND SAFETY OF ORIGINAL DRUG «ASPIRIN CARDIO» AND GENERIC«ACECARDOL» IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE | Abstract similar documents |
| N. A. Belolipetskiy, S. N. Tolpygina, O. А. Litinskaya, V. G. Belolipetskaya, S. Yu. Martsevich | ||
| "... Aim. To compare antiplatelet effect of two acetylsalicylic acid medicines, Acecardol ("Synthesis ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... therapy (TAT), selection of P2Y12 inhibitor, choice of oral anticoagulant to be combined with antiplatelet ..." | ||
| Vol 9, No 5 (2013) | CLINICAL IMPORTANCE OF ENDOTHELIAL DYSFUNCTION AND INSULIN RESISTANCE SYNDROME IN PATIENTS WITH GOUT ASSOCIATED WITH ARTERIAL HYPERTENSION | Abstract similar documents |
| N. N. Kushnarenko, A. V. Govorin | ||
| "... artery by ultrasonic Doppler examination. The level of nitrite-nitrate and endothelin-1 in blood serum ..." | ||
| Vol 15, No 1 (2019) | Atherosclerosis and Osteoporosis. Common Targets for the Effects of Cardiovascular and Anti-osteoporotic Drugs (Part I). The Effect of Cardiovascular Drugs on Bone Strength | Abstract similar documents |
| I. A. Skripnikova, N. A. Alikhanova, M. A. Kolchinа, M. A. Myagkova, O. V. Kosmatova | ||
| "... of cardiovascular drugs, such as statins, beta-blockers, ACE inhibitors, diuretics, calcium antagonists and nitrates ..." | ||
| Vol 12, No 4 (2016) | Adherence to attendance at outpatient clinic, quality of prehospital therapy, and direct outcome of acute coronary syndrome: analysis within LIS-3 registry | Abstract similar documents |
| Yu. V. Semenova, N. P. Kutishenko, A. V. Zagebelnyy, A. D. Deev, M. L. Ginzburg, S. Yu. Martsevich | ||
| "... infarction as an outcome of ACS. Taking antiplatelet agents, beta-blockers and long-acting nitrates before ..." | ||
| Vol 4, No 2 (2008) | THE CHOICE OF NITRATE THERAPY IN PATIENTS WITH STABLE ANGINA: COMPARATIVE STUDY OF ISOSORBIDE DINITRATE (IN USUAL TABLETS) WITH ISOSORBIDE-5-MONONITRATE (IN VARIOUS PRESENTATIONS) | Abstract similar documents |
| V. A. Egoro, E. V. Shilova, S. Y. Martsevich | ||
| Vol 18, No 6 (2022) | Perioperative Management of Patients Receiving Antithrombotic Therapy in Schemes and Algorithms | Abstract similar documents |
| O. N. Dzhioeva, E. A. Rogozhkina, O. M. Drapkina | ||
| "... of antiplatelet and/or anticoagulant drugs is a complicating factor in invasive and surgical procedures ..." | ||
| Vol 6, No 2 (2010) | EFFICACY AND SAFETY OF ACIDUM ACETYLSALICYLICUM USAGE | Abstract similar documents |
| V. N. Drozdov, V. A. Kim | ||
| "... Data about efficacy and safety of acetylsalicylic acid usage as antiplatelet drug and for cancer ..." | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents ..." | ||
| Vol 9, No 5 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| "... hospital. In specialized hospital the rate of aspirin use increased by 30%, statins - by 80%, beta-blockers ..." | ||
| Vol 3, No 4 (2007) | RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA | Abstract similar documents |
| N. F. Putchinyan, N. V. Furman, P. Ya. Dovgalevskyi | ||
| Vol 10, No 2 (2014) | ANALYSIS OF ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT ATRIAL FIBRILLATION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, A. S. Maslakov | ||
| "... .7%). Antiplatelet drugs were used in 25.4% of cases, including for patients with high risk of thromboembolic ..." | ||
| Vol 9, No 6 (2013) | PHARMACOTHERAPY AND OUTCOMES OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION – GENDER DIFFERENCES IN REAL CLINICAL PRACTICE | Abstract similar documents |
| P. V. Dolotovskaya, E. Y. Rudnichenko, N. V. Furman, O. V. Reshet'ko | ||
| "... improving STEMI prognosis - thrombolytics (21% vs 50%; p<0.05), statins (20% vs 53%; p<0.05), beta-blockers ..." | ||
| Vol 16, No 2 (2020) | LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period | Abstract similar documents |
| S. Yu. Martsevich, A. V. Zagrebelnyy, N. P. Zolotareva, N. P. Kutishenko, Yu. V. Lukina, M. L. Ginzburg, D. A. Startsev, S. V. Blagodatskikh | ||
| "... of nitrates decreased, and the use of statins increased (6.7% versus 13.9%, respectively, p>0.05). AMI ..." | ||
| Vol 7, No 3 (2011) | MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko | ||
| "... the need of dual antiplatelet agents therapy. ..." | ||
| Vol 6, No 6 (2010) | COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR) | Abstract similar documents |
| S. Yu. Martsevich, S. N. Tolpygina, E. S. Boychenko, R. E. Dubinskaya, Yu. V. Lukina, V. P. Voronina | ||
| "... Aim. To compare the antiplatelet efficacy of the original and generic enterosoluble tableted ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... antiplatelet therapy with acetyl salicylic acid and clopidogrel. Numerous clinical characteristics ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... value had 71 (68.3%) patients, HAS-BLED≥3 – 33 (31.7%). Only one antiplatelet agent was prescribed to 4 ..." | ||
| Vol 20, No 3 (2024) | Use of glycoprotein IIb/IIIa inhibitors in myocardial infarction in the Russian Federation, according to the Russian Registry of Acute Myocardial Infarction REGION-IM | Abstract similar documents |
| N. S. Kostritca, R. M. Rabinovich, R. M. Shakhnovich, I. S. Yavelov, R. G. Gulyan, Yu. K. Rytova, S. N. Tereschenko, A. D. Erlikh, D. V. Pevzner | ||
| Vol 13, No 3 (2017) | BETA-BLOCKERS AND RENOPROTECTION: THE POTENTIAL OF CARVEDILOL | Abstract similar documents |
| I. T. Murkamilov, I. S. Sabirov, V. V. Fomin, F. A. Yusupov | ||
| "... , antiproliferative, anti-apoptotic, antioxidant, antiplatelet and others. Carvedilol due to the vasodilating effect ..." | ||
| Vol 11, No 4 (2015) | INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev | ||
| "... of clopidogrel’s active metabolite and, respectively, its antiplatelet effect. We sought to determine the impact ..." | ||
| Vol 14, No 2 (2018) | WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| M. Yu. Gilyarov, Е. V. Konstantinova | ||
| "... atherosclerotic plaque. The use of acetylsalicylic acid with addition of the second antiplatelet agent, so-called ..." | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... K antagonists (such as warfarin), antiplatelet therapy (such as acetylsalicylic acid) and novel oral ..." | ||
| Vol 5, No 3 (2009) | FREE-RADICAL OXIDATION ACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITHOUT Q WAVE TREATED WITH EPROSARTAN OR ENALAPRIL ADDITIONALLY TO THE BASIC THERAPY | Abstract similar documents |
| O. G. Zaylobidinov, Yu. N. Ziyaev, N. K. Kamilova, A. S. Khalilov, B. F. Mukhamedova | ||
| "... daily). Basic therapy included anticoagulants, antiplatelets, beta-blockers, nitrates and statins ..." | ||
| Vol 15, No 6 (2019) | Possibilities of PRECISE-DAPT Score for Risk Prediction of Ischemic and Hemorrhagic Events in ST-Elevated Myocardial Infarction (According to the Data of the Registry Study in Kemerovo) | Abstract similar documents |
| D. Yu. Sedykh, V. V. Kashtalap, R. M. Velieva, O. L. Barbarash | ||
| "... , the peculiarities of double antiplatelet therapy (DAPT) prescription as well the incidence of ischemic ..." | ||
| Vol 14, No 5 (2018) | Drug Therapy Structure and Clinical Characteristics of Patients with Atrial Fibrillation According to Data of REKUR-AF Study | Abstract similar documents |
| I. L. Polshakova, S. V. Povetkin | ||
| "... scale – in 52.8%. Patients with AF most often received antiplatelet agents, angiotensinconverting ..." | ||
| Vol 18, No 1 (2022) | Polymorbidity and Polypragmasia in High and Very High Cardiovascular Risk Patients | Abstract similar documents |
| N. V. Izmozherova, A. A. Popov, A. A. Kuryndina, E. I. Gavrilova, M. A. Shambatov, V. M. Bakhtin | ||
| "... . Thus, 87.5% CHF patients were receiving renin-angiotensin-aldosterone system blockers. Statins were ..." | ||
| Vol 19, No 5 (2023) | Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes | Abstract similar documents |
| A. M. Kochergina, O. L. Barbarash | ||
| "... in the study (100 men (54,64%), 83 women (45,36%)). All patients were previously prescribed a statin ..." | ||
| Vol 7, No 5 (2011) | HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY | similar documents |
| G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, G. Sciascio | ||
| Vol 19, No 3 (2023) | Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, T. L. Stepuro, A. V. Kapytski | ||
| "... 19 + ITGA2 + eNOS genes (OR 5,1 (1,7214,96), p=0,0032) have higher risk of HRPR to dual antiplatelet ..." | ||
| Vol 6, No 5 (2010) | THE CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY 2010 IN STOCKHOLM: NEWS FOR PRACTITIONERS | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... significant events of the Congress are discussed. Symposia on antiplatelet therapy, hypertension, and recently ..." | ||
| Vol 4, No 2 (2008) | BETA-ADRENOBLOCKERS AND PLATELET AGGREGATION. CARVEDILOL | Abstract similar documents |
| A. N. Zakirova, F. S. Zarudij, B. N. Garifullin | ||
| "... . The current view on of beta-blocker antiplatelet effects is presented on the basis of physical and chemical ..." | ||
| Vol 4, No 3 (2008) | ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS | Abstract similar documents |
| V. A. Sulimov | ||
| "... Possibilities of modern antiplatelet and antithrombotic therapy at percutaneous coronary ..." | ||
| Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
| A. N. Meshkov | ||
| "... in atherosclerosis progression and thrombotic complications. That is why antiplatelet therapy is a necessary element ..." | ||
| Vol 14, No 3 (2018) | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, N. Yu. Voevodina, S. S. Sharonova | ||
| "... schemes and the preferred doses of statins and antiplatelet agents depending on the localization ..." | ||
| Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
| M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
| "... for resistance to antiplatelet therapy with clopidogrel. The decrease in the effectiveness of prolonged therapy ..." | ||
| Vol 2, No 4 (2006) | REPORT ON OPEN MULTICENTRAL RESEARCH PROGRAM “PRIORITY” IN CLINICAL PRACTICE. (PEKTROL – QUALITY OF LIFE IN PATIENTS WITH STABLE ANGINA PECTORIS TREATED WITH ISOSORBIDE-5-MONONITRATE IN LONG-ACTING PRESENTATION) | Abstract similar documents |
| Yu. A. Karpov | ||
| "... switching patients with stable angina from therapy with short-acting nitrates or isosorbide dinitrate ..." | ||
| Vol 8, No 2 (2012) | EFFICACY AND SAFETY OF ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES | Abstract similar documents |
| S. N. Tolpygina, S. Yu. Martsevich, E. N. Khoseva, N. V. Kiseleva | ||
| "... , as well as ways to improve the safety of antiplatelet therapy are presented, including use of enteric ..." | ||
| Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
| O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
| "... and the antiplatelet agent – acetylsalicylic acid, are highlighted on the basis of the results of clinical studies ..." | ||
| Vol 10, No 3 (2014) | THE CAPABILITIES OF A REGISTER AS A QUALITY CONTROL OF THE PHARMACOTHERAPY IN OUTPATIENTS AT HIGH RISK OF CARDIOVASCULAR COMPLICATIONS (THE "LIS-1" REGISTER) | Abstract similar documents |
| M. L. Ginzburg, S. Y. Martsevich, N. P. Kutishenko, Y. V. Lukina, A. D. Deev | ||
| "... myocardial infarction. As the number of patients receiving statins and antiplatelet agents was small ..." | ||
| Vol 8, No 6 (2012) | THE LIS STUDY (LYUBERTSY STUDY ON MORTALITY RATE IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION). EVALUATION OF DRUG THERAPY. PART 2. INFLUENCE OF PREVIOUS DRUG TREATMENT ON LONG-TERM LIFE PROGNOSIS | Abstract similar documents |
| S. Yu. Martsevich, M. L. Gynzburg, N. P. Kutishenko, A. D. Deev, V. P. Smirnov, L. U. Drozdova, E. V. Daniels, A. V. Fokina | ||
| "... ) rate of antiplatelet agents, ACE inhibitors, β-blockers and statins prescription exceeded 60 ..." | ||
| Vol 14, No 1 (2018) | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev | ||
| "... Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet ..." | ||
| Vol 9, No 2 (2013) | ANTITHROMBOTIC THERAPY SAFETY MONITORING BASED ON SPONTANEOUS REPORTS | Abstract similar documents |
| O. V. Shatalova, O. N. Smuseva, A. S. Maslakov | ||
| "... .2% (4/18), and antiplatelet drugs 11.1% (2/18). Conclusion. Warfarin was more often cause of ADR during ..." | ||
| Vol 9, No 2 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER. (Part 1) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| "... of cardiovascular complications (antiplatelets, β-blockers, ACE inhibitors, statins) were not often prescribed ..." | ||
| Vol 10, No 6 (2014) | CHANGES IN PREHOSPITAL PHARMACOTHERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN 2005-2014 ACCORDING TO THE LIS REGISTER | Abstract similar documents |
| S. Y. Martsevich, M. L. Ginzburg, N. P. Kutishenko, A. V. Zagrebelnyy, I. S. Balashov, L. G. Garkina | ||
| "... . The positive changes in the prescription of antiplatelet agents (13.5% in 2005 and 27.4% in 2014), statins (1 ..." | ||
| Vol 7, No 1 (2011) | THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY | Abstract similar documents |
| V. V. Yakusevich, A. S. Petrochenko, V. A. Simonov, N. Yu. Levshin, A. D. Deev | ||
| "... half of the patients received the drugs in reverse order. Antiplatelet activity of Plavix and Egitromb ..." | ||
| Vol 13, No 6 (2017) | ASSESSMENT OF CHANGES IN QUALITY OF PREHOSPITAL TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME IN THE LAST FEW YEARS: LIS-1 VS LIS-3 REGISTRIES | Abstract similar documents |
| Yu. V. Semenova, A. V. Zagrebelnyy, N. P. Kutishenko, M. L. Ginzburg, S. Yu. Martsevich | ||
| "... in the LIS-1 registry, more often took antiplatelet drugs (23.2% vs 15.7%, respectively; p<0.01) and statins ..." | ||
| Vol 16, No 2 (2020) | Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev | ||
| "... the follow-up. Their number was comparable in individuals taking antiplatelet agents and direct oral ..." | ||
| 1 - 100 of 153 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
.jpg)
